Bethanechol transmucosal - Acacia Pharma

Drug Profile

Bethanechol transmucosal - Acacia Pharma

Alternative Names: APD 515

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acacia Pharma
  • Class Neuroprotectants; Small molecules; Trimethyl ammonium compounds
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Xerostomia

Most Recent Events

  • 20 Aug 2015 Phase-II development is ongoing for Xerostomia in Europe
  • 15 Oct 2013 Final Efficacy and Adverse events data from a proof-of-concept phase II trial in Xerostomia (in patients with advanced cancer) released by Acacia Pharma
  • 03 Sep 2013 Acacia Pharma secures loan (£15 million) from Fidelity Biosciences and Novo A/S to finance development of APD 515 for Xerostomia, as well as amisulpride (as APD 421 and APD 403)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top